神经降压素受体激动剂ABS 201诱导的药物性低温对心肺复苏结局的影响
研究在大鼠心室颤动心脏骤停(VFCA)模型中进行,12只大鼠经电诱发室颤、6分钟心肺复苏后除颤成功,复苏后随机接受ABS 201(8 mg/kg/h)或安慰剂。给予ABS 201后血温从37°C显著降至34°C并维持2.5小时,治疗组复苏后心肌功能障碍、神经功能缺损评分(NDS)及生存时间均显著改善。作者认为ABS 201可诱导治疗性低温,改善复苏后心-神经功能并延长生存时间,可能成为现有降温方法之外诱导治疗性低温的替代方法。
要点
- 在心室颤动心脏骤停大鼠模型中,复苏后给予ABS 201(8 mg/kg/h)使血温从37°C降至34°C并维持2.5小时。
- ABS 201治疗组复苏后心肌功能障碍、神经功能缺损评分(NDS)及生存时间均较安慰剂组显著改善。
- 研究共12只大鼠,室颤经电诱发,心肺复苏6分钟后除颤成功,复苏后随机分组。
- 作者认为ABS 201可能成为现有降温方法之外诱导治疗性低温的替代方法,以改善复苏后结局。
适用人群与场景
- 心室颤动心脏骤停(VFCA)大鼠模型,电诱发室颤、心肺复苏6分钟后除颤成功复苏的动物。
处置流程与药物剂量
- 复苏成功后随机给予ABS 201 8 mg/kg/h或安慰剂。
- 给予ABS 201后血温由37°C降至34°C,并维持2.5小时。
- 观察复苏后心肌功能、神经功能缺损评分(NDS)及长达72小时的生存时间。
研究设计与关键结果
- 研究为心室颤动心脏骤停大鼠模型,共12只大鼠,电诱发室颤,心肺复苏6分钟后除颤成功,复苏后随机接受ABS 201(8 mg/kg/h)或安慰剂。
- 给予ABS 201后血温从37°C显著降至34°C,并维持2.5小时。
- ABS 201治疗组复苏后心肌功能障碍、神经功能缺损评分(NDS)及生存时间均显著改善。
- 作者结论为ABS 201可诱导治疗性低温、改善复苏后心肌-神经功能障碍并延长生存时间。
证据类型、等级与局限
- 证据类型:动物实验(大鼠心室颤动心脏骤停模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为ABS 201可能成为现有降温方法之外诱导治疗性低温的替代方法,以改善复苏后结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Neurotensin is an endogenous tridecapeptide that binds to neurotensin receptors in the brain, which induce hypothermia. The aim of this study was to investigate whether the receptor agonist ABS 201 could induce therapeutic hypothermia and improve postresuscitation outcomes in a ventricular fibrillation cardiac arrest (VFCA) rat model. VF was electrically induced in 12 rats. Defibrillation was achieved after 6 min of cardiopulmonary resuscitation. After successful resuscitation, animals were randomized to receive ABS 201 (8 mg/kg/h) or placebo. Postresuscitation myocardial function and neurological deficit scores (NDS) were assessed, and postresuscitation survival duration was observed for up to 72 h. After administration of ABS 201, blood temperature decreased significantly from 37°C to 34°C, and was maintained for 2.5 h. There was a significant improvement of postresuscitation myocardial dysfunction, NDS, and survival duration in animals treated with ABS 201. These results demonstrated that ABS 201 induces therapeutic hypothermia in a VFCA rat model, ameliorates postresuscitation myocardial-neurological dysfunction, and prolongs survival duration. ABS 201 may therefore be an alternative method to induce therapeutic hypothermia with current cooling methods and improve postresuscitation outcomes.
参考来源
- Li H, Hua T, Wang W, et al. The Effects of Pharmacological Hypothermia Induced by Neurotensin Receptor Agonist ABS 201 on Outcomes of CPR. Shock. 2019. PMID: 30986796. doi:10.1097/SHK.0000000000001178
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。